ENVVENO MEDICAL CORP (NVNO) Stock Price & Overview
NASDAQ:NVNO • US29415J2050
Current stock price
The current stock price of NVNO is 12.9 USD. Today NVNO is down by -0.08%. In the past month the price increased by 11.68%. In the past year, price decreased by -86.51%.
NVNO Key Statistics
- Market Cap
- 8.514M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -44.45
- Dividend Yield
- N/A
NVNO Stock Performance
NVNO Stock Chart
NVNO Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to NVNO. When comparing the yearly performance of all stocks, NVNO is a bad performer in the overall market: 92.57% of all stocks are doing better.
NVNO Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NVNO. NVNO has a great financial health rating, but its profitability evaluates not so good.
NVNO Earnings
NVNO Forecast & Estimates
NVNO Groups
Sector & Classification
NVNO Financial Highlights
Over the last trailing twelve months NVNO reported a non-GAAP Earnings per Share(EPS) of -44.45. The EPS increased by 35.2% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -65.87% | ||
| ROE | -71.77% | ||
| Debt/Equity | 0 |
NVNO Ownership
NVNO Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 14.67 | 161.117B | ||
| ISRG | INTUITIVE SURGICAL INC | 41.73 | 160.285B | ||
| SYK | STRYKER CORP | 21.93 | 125.349B | ||
| BSX | BOSTON SCIENTIFIC CORP | 18.58 | 88.457B | ||
| EW | EDWARDS LIFESCIENCES CORP | 26.91 | 45.956B | ||
| IDXX | IDEXX LABORATORIES INC | 38.95 | 45.191B | ||
| BDX | BECTON DICKINSON AND CO | 11.39 | 44.616B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 13.8 | 32.972B | ||
| RMD | RESMED INC | 18.12 | 32.227B | ||
| DXCM | DEXCOM INC | 24.75 | 24.092B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.03 | 17.942B | ||
| PODD | INSULET CORP | 29.89 | 13.321B | ||
| PEN | PENUMBRA INC | 65.31 | 12.858B |
Related stock screener links
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About NVNO
Company Profile
enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 37 full-time employees. The company went IPO on 2018-05-31. The firm is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The firm is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The firm is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
Company Info
IPO: 2018-05-31
ENVVENO MEDICAL CORP
70 Doppler
Irvine CALIFORNIA US
CEO: Robert Berman
Employees: 33
Phone: 19492612900
ENVVENO MEDICAL CORP / NVNO FAQ
Can you describe the business of ENVVENO MEDICAL CORP?
enVVeno Medical Corp. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. The company is headquartered in Irvine, California and currently employs 37 full-time employees. The company went IPO on 2018-05-31. The firm is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The firm is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The firm is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.
What is the current price of NVNO stock?
The current stock price of NVNO is 12.9 USD. The price decreased by -0.08% in the last trading session.
What is the dividend status of ENVVENO MEDICAL CORP?
NVNO does not pay a dividend.
How is the ChartMill rating for ENVVENO MEDICAL CORP?
NVNO has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does ENVVENO MEDICAL CORP belong to?
ENVVENO MEDICAL CORP (NVNO) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
What is ENVVENO MEDICAL CORP worth?
ENVVENO MEDICAL CORP (NVNO) has a market capitalization of 8.51M USD. This makes NVNO a Nano Cap stock.
What is the outstanding short interest for ENVVENO MEDICAL CORP?
The outstanding short interest for ENVVENO MEDICAL CORP (NVNO) is 14.65% of its float.